Opinion|Videos|August 23, 2024
Implementing Proactive Management Strategies with Amivantamab in Clinical Practice: Expert Insights
Author(s)Martin Dietrich, MD, PhD, Wade Iams, MD
Wade T. Iams, MD, provides clinical insights on proactive management strategies for patients receiving amivantamab for advanced EGFR-mutant NSCLC.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do you incorporate proactive management strategies into your practice setting?
- What challenges have you faced when integrating proactive management strategies into the clinical practice setting?
- What tools/resources would be helpful in overcoming these?
Advertisement
Related to this article
The oral KRAS G12D inhibitor VS-7375 produced responses in pancreatic, colorectal, and lung cancers in the phase 1/2 TARGET-D 101 trial.
Experts discuss why the convenience of the all-oral decitabine/cedazuridine plus venetoclax regimen does not reduce the need for close monitoring in AML.
Dan Costin, MD, discusses where personalized mRNA vaccines could fit into lung cancer care within 5 to 10 years.
Dan Costin, MD, describes counseling his first patient on a personalized mRNA vaccine vs observation in the INTerpath-014 trial.
The phase 3 FURVENT trial showed an objective response rate benefit with firmonertinib in EGFR exon 20 insertion–mutant NSCLC.
Dan Costin, MD, explains the rationale for testing a personalized mRNA vaccine after resection of high-risk stage I NSCLC.
Data from the REZILIENT3 trial support the NDA for zipalertinib plus chemotherapy for those with NSCLC harboring EGFR exon 20 insertion mutations.
Xiuning Le, MD, PhD, discusses the accelerated approval of frontline sevabertinib for patients with HER2-mutated non–small cell lung cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Reading a Changed Eye Examination and Impact on Therapy
2
FDA Expands Approval for Nogapendekin Alfa in BCG-Unresponsive NMIBC
3
VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors
4
Operationalizing the First Dose and Building the Oncology and Eye Care Partnership
5